Connecting the Dots: How Injury in the Arterial Wall Contributes to Atherosclerotic Disease
Clin Ther. 2023 Oct 25:S0149-2918(23)00396-X. doi: 10.1016/j.clinthera.2023.10.004. Online ahead of print.ABSTRACTPURPOSE: The occurrence and development of atherosclerotic cardiovascular disease, which can result in severe outcomes, such as myocardial infarction, stroke, loss of limb, renal failure, and infarction of the gut, are strongly associated with injury to the intimal component of the arterial wall whether via the inside-out or outside-in pathways. The role of injury to the tunica media as a pathway of atherosclerosis initiation is an underresearched area. This review focuses on potential pathways to vessel wall i...
Source: Clinical Therapeutics - October 27, 2023 Category: Drugs & Pharmacology Authors: Hanane Belhoul-Fakir Michael Lawrence Brown Peter L Thompson Juliana Hamzah Shirley Jansen Source Type: research
Safety and Efficacy of Direct Oral Anticoagulant in Addition to Antiplatelet Therapy After Acute Coronary Syndrome: A Systemic Review and Meta-analysis of 53,869 Patients
This study aims to assess the efficacy and safety of DOACs plus antiplatelet treatment (APT) after ACS.METHODS: A systematic literature search was conducted to identify randomized clinical trials comparing DOACs plus APT with APT alone after ACS. The primary efficacy end points were cardiovascular mortality, myocardial infarction, all-cause mortality, and stroke and systemic embolization (SSE). The primary safety end point was major bleeding. The random-effects model was used to calculate relative risk (RR) and corresponding 95% CIs.RESULTS: Nine trials with a total of 53,869 patients were identified, with 33,011 (61.2%) i...
Source: Clinical Therapeutics - October 25, 2023 Category: Drugs & Pharmacology Authors: Abdulmajeed Alharbi Mohammed Mhanna Mohammed Alyosif Clarissa Pena Abed Jabr Anas Alsughayer Halah Alfatlawi Mohammad Safi Abdulaziz Aldhafeeri Neha Patel Sadik Khuder Ehab Eltahawy Source Type: research
Safety and Efficacy of Direct Oral Anticoagulant in Addition to Antiplatelet Therapy After Acute Coronary Syndrome: A Systemic Review and Meta-analysis of 53,869 Patients
This study aims to assess the efficacy and safety of DOACs plus antiplatelet treatment (APT) after ACS.METHODS: A systematic literature search was conducted to identify randomized clinical trials comparing DOACs plus APT with APT alone after ACS. The primary efficacy end points were cardiovascular mortality, myocardial infarction, all-cause mortality, and stroke and systemic embolization (SSE). The primary safety end point was major bleeding. The random-effects model was used to calculate relative risk (RR) and corresponding 95% CIs.RESULTS: Nine trials with a total of 53,869 patients were identified, with 33,011 (61.2%) i...
Source: Clinical Therapeutics - October 25, 2023 Category: Drugs & Pharmacology Authors: Abdulmajeed Alharbi Mohammed Mhanna Mohammed Alyosif Clarissa Pena Abed Jabr Anas Alsughayer Halah Alfatlawi Mohammad Safi Abdulaziz Aldhafeeri Neha Patel Sadik Khuder Ehab Eltahawy Source Type: research
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis
This study evaluates the efficacy and tolerability of cyclosporine A cationic emulsion (CsA-CE) in patients ≥4 years of age with moderate-to-severe vernal keratoconjunctivitis (VKC).METHODS: This Phase II/III, multicenter, double-masked, dose-ranging study had 2 treatment periods: a 4-week, randomized, vehicle-controlled period in which patients received 0.05% CsA-CE, 0.1% CsA-CE, or vehicle eye drops 4 times daily (period 1) and a 3-month period in which patients received 0.05% CsA-CE or 0.1% CsA-CE 2 or 4 times daily (period 2). The primary efficacy end point was rating of subjective symptoms at day 28 in period 1 per ...
Source: Clinical Therapeutics - October 23, 2023 Category: Drugs & Pharmacology Authors: Andrea Leonardi Pierre-Jean Pisella Jos é Manuel Benítez-Del-Castillo Mourad Amrane Dahlia Ismail Serge Doan Dominique Bremond-Gignac Source Type: research
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis
This study evaluates the efficacy and tolerability of cyclosporine A cationic emulsion (CsA-CE) in patients ≥4 years of age with moderate-to-severe vernal keratoconjunctivitis (VKC).METHODS: This Phase II/III, multicenter, double-masked, dose-ranging study had 2 treatment periods: a 4-week, randomized, vehicle-controlled period in which patients received 0.05% CsA-CE, 0.1% CsA-CE, or vehicle eye drops 4 times daily (period 1) and a 3-month period in which patients received 0.05% CsA-CE or 0.1% CsA-CE 2 or 4 times daily (period 2). The primary efficacy end point was rating of subjective symptoms at day 28 in period 1 per ...
Source: Clinical Therapeutics - October 23, 2023 Category: Drugs & Pharmacology Authors: Andrea Leonardi Pierre-Jean Pisella Jos é Manuel Benítez-Del-Castillo Mourad Amrane Dahlia Ismail Serge Doan Dominique Bremond-Gignac Source Type: research
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis
This study evaluates the efficacy and tolerability of cyclosporine A cationic emulsion (CsA-CE) in patients ≥4 years of age with moderate-to-severe vernal keratoconjunctivitis (VKC).METHODS: This Phase II/III, multicenter, double-masked, dose-ranging study had 2 treatment periods: a 4-week, randomized, vehicle-controlled period in which patients received 0.05% CsA-CE, 0.1% CsA-CE, or vehicle eye drops 4 times daily (period 1) and a 3-month period in which patients received 0.05% CsA-CE or 0.1% CsA-CE 2 or 4 times daily (period 2). The primary efficacy end point was rating of subjective symptoms at day 28 in period 1 per ...
Source: Clinical Therapeutics - October 23, 2023 Category: Drugs & Pharmacology Authors: Andrea Leonardi Pierre-Jean Pisella Jos é Manuel Benítez-Del-Castillo Mourad Amrane Dahlia Ismail Serge Doan Dominique Bremond-Gignac Source Type: research
Effects of Transdermal 17 β-Estradiol + Norethisterone Acetate on Cardiovascular Disease Risk Factors in Postmenopausal Women: A Meta-Analysis of Data From Randomized, Controlled Trials
Clin Ther. 2023 Oct 16:S0149-2918(23)00347-8. doi: 10.1016/j.clinthera.2023.09.002. Online ahead of print.ABSTRACTPURPOSE: To date, no study has demonstrated the role of transdermal 17β-estradiol + norethisterone acetate on all of the risk factors for cardiovascular disease in postmenopausal women. To overcome this knowledge gap, a systematic review and meta-analysis were conducted to determine the effects of this combination treatment on BMI, body weight, waist/hip ratio, fibrinogen, factor VII, lipoprotein(a), fasting blood sugar, insulin, HbA1c, TG, LDL-C, HDL-C, and TC in postmenopausal women.METHODS: PubMed/Medline, ...
Source: Clinical Therapeutics - October 18, 2023 Category: Drugs & Pharmacology Authors: XiaoHong Lan Shan Cai Guoxing Li Kousalya Prabahar Benjamin Hern ández-Wolters Yanru Yin Source Type: research
Effects of Transdermal 17 β-Estradiol + Norethisterone Acetate on Cardiovascular Disease Risk Factors in Postmenopausal Women: A Meta-Analysis of Data From Randomized, Controlled Trials
Clin Ther. 2023 Oct 16:S0149-2918(23)00347-8. doi: 10.1016/j.clinthera.2023.09.002. Online ahead of print.ABSTRACTPURPOSE: To date, no study has demonstrated the role of transdermal 17β-estradiol + norethisterone acetate on all of the risk factors for cardiovascular disease in postmenopausal women. To overcome this knowledge gap, a systematic review and meta-analysis were conducted to determine the effects of this combination treatment on BMI, body weight, waist/hip ratio, fibrinogen, factor VII, lipoprotein(a), fasting blood sugar, insulin, HbA1c, TG, LDL-C, HDL-C, and TC in postmenopausal women.METHODS: PubMed/Medline, ...
Source: Clinical Therapeutics - October 18, 2023 Category: Drugs & Pharmacology Authors: XiaoHong Lan Shan Cai Guoxing Li Kousalya Prabahar Benjamin Hern ández-Wolters Yanru Yin Source Type: research
Effects of Transdermal 17 β-Estradiol + Norethisterone Acetate on Cardiovascular Disease Risk Factors in Postmenopausal Women: A Meta-Analysis of Data From Randomized, Controlled Trials
Clin Ther. 2023 Oct 16:S0149-2918(23)00347-8. doi: 10.1016/j.clinthera.2023.09.002. Online ahead of print.ABSTRACTPURPOSE: To date, no study has demonstrated the role of transdermal 17β-estradiol + norethisterone acetate on all of the risk factors for cardiovascular disease in postmenopausal women. To overcome this knowledge gap, a systematic review and meta-analysis were conducted to determine the effects of this combination treatment on BMI, body weight, waist/hip ratio, fibrinogen, factor VII, lipoprotein(a), fasting blood sugar, insulin, HbA1c, TG, LDL-C, HDL-C, and TC in postmenopausal women.METHODS: PubMed/Medline, ...
Source: Clinical Therapeutics - October 18, 2023 Category: Drugs & Pharmacology Authors: XiaoHong Lan Shan Cai Guoxing Li Kousalya Prabahar Benjamin Hern ández-Wolters Yanru Yin Source Type: research
Effects of Transdermal 17 β-Estradiol + Norethisterone Acetate on Cardiovascular Disease Risk Factors in Postmenopausal Women: A Meta-Analysis of Data From Randomized, Controlled Trials
Clin Ther. 2023 Oct 16:S0149-2918(23)00347-8. doi: 10.1016/j.clinthera.2023.09.002. Online ahead of print.ABSTRACTPURPOSE: To date, no study has demonstrated the role of transdermal 17β-estradiol + norethisterone acetate on all of the risk factors for cardiovascular disease in postmenopausal women. To overcome this knowledge gap, a systematic review and meta-analysis were conducted to determine the effects of this combination treatment on BMI, body weight, waist/hip ratio, fibrinogen, factor VII, lipoprotein(a), fasting blood sugar, insulin, HbA1c, TG, LDL-C, HDL-C, and TC in postmenopausal women.METHODS: PubMed/Medline, ...
Source: Clinical Therapeutics - October 18, 2023 Category: Drugs & Pharmacology Authors: XiaoHong Lan Shan Cai Guoxing Li Kousalya Prabahar Benjamin Hern ández-Wolters Yanru Yin Source Type: research
Personalized Minimal Effective Concentration Therapy
Clin Ther. 2023 Oct 12:S0149-2918(23)00379-X. doi: 10.1016/j.clinthera.2023.09.015. Online ahead of print.ABSTRACTIt has been recognized for literally centuries that patients should be given only the amount of medication necessary to treat disease(s) or relieve symptoms. It is also well known that this amount can vary greatly between patients or even over time in the same patient. The ability to identify this amount, that is, to "personalize" dosing, requires a reliable measure of a patient's response to treatment. The development of analytical methods for the accurate measurement of pharmacologically meaningful drug conce...
Source: Clinical Therapeutics - October 14, 2023 Category: Drugs & Pharmacology Authors: Philip D Walson Source Type: research
Intensify Standardized Anticoagulation for Cancer-Associated Pulmonary Embolism: From Single-Center Real-World Data
Clin Ther. 2023 Oct 12:S0149-2918(23)00378-8. doi: 10.1016/j.clinthera.2023.09.014. Online ahead of print.ABSTRACTPURPOSE: Pulmonary embolism (PE) is a significant contributor to mortality in patients with cancer. Although anticoagulation serves as the cornerstone of treatment for cancer-associated PE, it has not been emphasized in real-world settings. The aim of this study was to examine the impact of suboptimal anticoagulant treatment on the prognosis of cancer-associated PE.METHODS: A cohort of 356 individuals newly diagnosed with acute PE were enrolled. The primary outcome of the study was recurrent venous thromboembol...
Source: Clinical Therapeutics - October 14, 2023 Category: Drugs & Pharmacology Authors: Mingjie Liu Xianming Qiu Yuanyuan Sun Qi Li Jing Wen Guixiang Liu Zhouhong Yao Ling Zhu Source Type: research
Personalized Minimal Effective Concentration Therapy
Clin Ther. 2023 Oct 12:S0149-2918(23)00379-X. doi: 10.1016/j.clinthera.2023.09.015. Online ahead of print.ABSTRACTIt has been recognized for literally centuries that patients should be given only the amount of medication necessary to treat disease(s) or relieve symptoms. It is also well known that this amount can vary greatly between patients or even over time in the same patient. The ability to identify this amount, that is, to "personalize" dosing, requires a reliable measure of a patient's response to treatment. The development of analytical methods for the accurate measurement of pharmacologically meaningful drug conce...
Source: Clinical Therapeutics - October 14, 2023 Category: Drugs & Pharmacology Authors: Philip D Walson Source Type: research
Intensify Standardized Anticoagulation for Cancer-Associated Pulmonary Embolism: From Single-Center Real-World Data
Clin Ther. 2023 Oct 12:S0149-2918(23)00378-8. doi: 10.1016/j.clinthera.2023.09.014. Online ahead of print.ABSTRACTPURPOSE: Pulmonary embolism (PE) is a significant contributor to mortality in patients with cancer. Although anticoagulation serves as the cornerstone of treatment for cancer-associated PE, it has not been emphasized in real-world settings. The aim of this study was to examine the impact of suboptimal anticoagulant treatment on the prognosis of cancer-associated PE.METHODS: A cohort of 356 individuals newly diagnosed with acute PE were enrolled. The primary outcome of the study was recurrent venous thromboembol...
Source: Clinical Therapeutics - October 14, 2023 Category: Drugs & Pharmacology Authors: Mingjie Liu Xianming Qiu Yuanyuan Sun Qi Li Jing Wen Guixiang Liu Zhouhong Yao Ling Zhu Source Type: research
Personalized Minimal Effective Concentration Therapy
Clin Ther. 2023 Oct 12:S0149-2918(23)00379-X. doi: 10.1016/j.clinthera.2023.09.015. Online ahead of print.ABSTRACTIt has been recognized for literally centuries that patients should be given only the amount of medication necessary to treat disease(s) or relieve symptoms. It is also well known that this amount can vary greatly between patients or even over time in the same patient. The ability to identify this amount, that is, to "personalize" dosing, requires a reliable measure of a patient's response to treatment. The development of analytical methods for the accurate measurement of pharmacologically meaningful drug conce...
Source: Clinical Therapeutics - October 14, 2023 Category: Drugs & Pharmacology Authors: Philip D Walson Source Type: research
